News | January 01, 2025
Merck inks agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Merck will record a pre-tax charge relating to the upfront payment of $588 million
Merck has also decided to end the favezelimab clinical development program
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
The initiative will encourage and motivate emerging biotech startups, innovators and entrepreneurs
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
With the addition of Karsanbhai, the Merck board will consist of 13 members
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Subscribe To Our Newsletter & Stay Updated
